Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Switch Pocket Inhibitors of the ABL Tyrosine Kinase: Distinct Kinome Inhibition Profiles and in Vivo Efficacy in Mouse Models of CML and B-Lymphoblastic Leukemia Induced by BCR-ABL T315I

Richard A. Van Etten, MD, PhD, Wayne W. Chan, BA, Virginia M. Zaleskas, MD, Christoph Walz, MD, Peter Evangelista, BA, Katherine Lazarides, BS, Monica Betancur, MS, Scott Wise, MS, Peter A. Petillo, PhD, Daniel L. Flynn, PhD

Blood (2008) 112 (11): 576.

https://doi.org/10.1182/blood.V112.11.576.576

Published: 2008

Journal Articles

DCC-2036: A Novel Switch Pocket Inhibitor of ABL Tyrosine Kinase with Therapeutic Efficacy Against BCR-ABL T315I In Vitro and in a CML Mouse Model.

Richard A. Van Etten, MD, PhD, Wayne W. Chan, BS, Virginia M. Zaleskas, MD, PhD, Peter Evangelista, BS, Katherine Lazarides, BS, Cong Peng, PhD, Shaoguang Li, MD, PhD, Scott C. Wise, PhD, Peter Petillo, PhD, Daniel L. Flynn, PhD

Blood (2007) 110 (11): 463.

https://doi.org/10.1182/blood.V110.11.463.463

Published: 2007

Journal Articles

A Selective and Potent Oral Inhibitor of the JAK2 Tyrosine Kinase Reverses Polycythemia and Leukocytosis Induced by JAK2 V617F in a Mouse Model.

Virginia M. Zaleskas, MD, Wayne W. Chan, BS, Peter Evangelista, BS, Katherine Lazarides, BS, Rajesh Chopra, MD, Michael Zinda, PhD, Dennis Huszar, PhD, Richard A. Van Etten, MD PhD

Blood (2007) 110 (11): 557.

https://doi.org/10.1182/blood.V110.11.557.557

Published: 2007

Journal Articles

CD44 Is Selectively Required for the Homing and Engraftment of BCR-ABL-Expressing Leukemic Stem Cells.

Daniela S. Krause, MD, PhD, Katherine Lazarides, BS, Ulrich H. von Andrian, MD, PhD, Richard A. Van Etten, MD, PhD

Blood (2006) 108 (11): 743.

https://doi.org/10.1182/blood.V108.11.743.743

Published: 2006

Journal Articles

Molecular Pathogenesis of Polycythemia Induced in Mice by JAK2 V617F.

Virginia M. Zaleskas, MD, Daniela S. Krause, MD, PhD, Katherine Lazarides, BS, Nihal Patel, BS, Yiguo Hu, BS, Shaoguang Li, MD, PhD, Richard A. Van Etten, MD, PhD

Blood (2005) 106 (11): 116.

https://doi.org/10.1182/blood.V106.11.116.116

Published: 2005

NARROW

Switch Pocket Inhibitors of the ABL Tyrosine Kinase: Distinct Kinome Inhibition Profiles and in Vivo Efficacy in Mouse Models of CML and B-Lymphoblastic Leukemia Induced by BCR-ABL T315I

DCC-2036: A Novel Switch Pocket Inhibitor of ABL Tyrosine Kinase with Therapeutic Efficacy Against BCR-ABL T315I In Vitro and in a CML Mouse Model.

A Selective and Potent Oral Inhibitor of the JAK2 Tyrosine Kinase Reverses Polycythemia and Leukocytosis Induced by JAK2 V617F in a Mouse Model.

CD44 Is Selectively Required for the Homing and Engraftment of BCR-ABL-Expressing Leukemic Stem Cells.

Molecular Pathogenesis of Polycythemia Induced in Mice by JAK2 V617F.

Email alerts

ASH Publications

American Society of Hematology

Switch Pocket Inhibitors of the ABL Tyrosine Kinase: Distinct Kinome Inhibition Profiles and in Vivo Efficacy in Mouse Models of CML and B-Lymphoblastic Leukemia Induced by BCR-ABL T315I

DCC-2036: A Novel Switch Pocket Inhibitor of ABL Tyrosine Kinase with Therapeutic Efficacy Against BCR-ABL T315I In Vitro and in a CML Mouse Model.

A Selective and Potent Oral Inhibitor of the JAK2 Tyrosine Kinase Reverses Polycythemia and Leukocytosis Induced by JAK2 V617F in a Mouse Model.

CD44 Is Selectively Required for the Homing and Engraftment of BCR-ABL-Expressing Leukemic Stem Cells.

Molecular Pathogenesis of Polycythemia Induced in Mice by JAK2 V617F.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only